中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

111 records (took 0.031 seconds)

    METHODS FOR CANCER PROGNOSIS AND DIAGNOSIS
    63.
    发明申请
    METHODS FOR CANCER PROGNOSIS AND DIAGNOSIS 审中-公开
    癌症预防与诊断方法

    公开(公告)号：WO0133228A2

    公开(公告)日：2001-05-10

    申请号：PCT/US0030467

    申请日：2000-11-03

    Applicant: ONCOTECH INC ,  FRUEHAUF JOHN ,  MECHETNER EUGENE

    Inventor： FRUEHAUF JOHN ,  MECHETNER EUGENE

    IPC: C12Q1/68 ,  G01N33/50 ,  G01N33/569 ,  G01N33/574

    CPC classification number: G01N33/5091 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/142 ,  C12Q2600/158 ,  G01N33/574 ,  G01N2333/4718 ,  G01N2800/44 ,  G01N2800/52

    Abstract: Methods for separating living neoplastic cells from dead cells in a tumor sample, using a "vital stain" (e.g. propidium iodide) are provided. These methods are useful for prognosis, diagnosis, assessment of staging and disease progression in human cancer patients. The first method is a generic method involving antibodies that specifically bind neoplastic cells. The second method is a specific method to test the resistance of neoplastic cells to cytotoxic compounds using antibodies against a discrimination compound for apoptotic cells (e.g. Annexin V). The second method also determines the gene profile after cell sorting using a hybridisation array. The difference in gene expression between drug resistant and drug sensitive tumor cells can thus be employed to make clinical decisions.

    Abstract translation: 提供了使用“生命染色剂”（例如碘化丙啶）将活肿瘤细胞从肿瘤样品中的死细胞分离的方法。 这些方法可用于预后，诊断，评估人类癌症患者的分期和疾病进展。 第一种方法是涉及特异性结合肿瘤细胞的抗体的通用方法。 第二种方法是使用针对凋亡细胞的鉴别化合物的抗体（例如膜联蛋白V）来测试肿瘤细胞对细胞毒性化合物的抗性的具体方法。 第二种方法还使用杂交阵列确定细胞分选后的基因谱。 因此，可以使用耐药性和药物敏感性肿瘤细胞之间的基因表达的差异来作出临床决定。

    MODULATORS OF TUMOR IMMUNE RESISTANCE FOR THE TREATMENT OF CANCER
    64.
    发明申请
    MODULATORS OF TUMOR IMMUNE RESISTANCE FOR THE TREATMENT OF CANCER 审中-公开
    肿瘤免疫耐受调节剂治疗肿瘤的研究

    公开(公告)号：WO2017140803A1

    公开(公告)日：2017-08-24

    申请号：PCT/EP2017/053540

    申请日：2017-02-16

    Applicant: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS

    Inventor： KHANDELWAL, Nisit ,  BECKHOVE, Philipp ,  BOUTROS, Michael ,  BREINIG, Marco ,  MICHELS, Tillmann

    IPC: A61K31/4375 ,  A61K31/517 ,  A61K31/713 ,  A61K39/00 ,  A61K45/06 ,  G01N33/50

    CPC classification number: A61K31/4375 ,  A61K31/517 ,  A61K31/713 ,  A61K45/06 ,  G01N33/50 ,  G01N33/5008 ,  G01N2800/44 ,  G01N2800/52 ,  A61K2300/00

    Abstract: The present invention pertains to novel modulators of tumor resistance against T-cell mediated cytotoxic immune responses. The invention provides antagonists of tumor immune escape mechanisms and methods and other aspects related thereto, and therefore provides novel approaches for treating or aiding a treatment of various cancerous diseases and/or the diagnosis thereof. The invention pertains to both negative and positive regulators of tumor cell resistance and suggests the use inhibitors or activators of these genes for therapeutic purposes. Inparticular aspects, the invention provides combination therapeutics and/or therapies involving such inhibitors or activators. The invention furthermore provides screening methods for novel cancer therapeutics modulating the action of the identified genes,diagnostic approaches to detect cancer resistance to cytotoxic T-cells as well as pharmaceutical compositions and diagnostic kits, for use with or related to for performing these methods.

    Abstract translation: 本发明涉及针对T细胞介导的细胞毒性免疫应答的肿瘤抗性的新型调节剂。 本发明提供了肿瘤免疫逃避机制和方法及其相关方面的拮抗剂，并因此提供了治疗或帮助治疗各种癌性疾病和/或其诊断的新方法。 本发明涉及肿瘤细胞抗性的阴性和阳性调节剂，并且提出使用这些基因的抑制剂或激活剂用于治疗目的。 具体而言，本发明提供涉及这种抑制剂或活化剂的组合治疗剂和/或疗法。 本发明还提供了用于调节所鉴定的基因的作用的新型癌症治疗剂的筛选方法，检测对细胞毒性T细胞的癌症抗性的诊断方法以及用于执行这些方法或与其相关的药物组合物和诊断试剂盒。 / p>

    METHOD FOR RAPID IDENTIFICATION OF DRUG TARGETS AND DRUG MECHANISMS OF ACTION IN HUMAN CELLS
    69.
    发明申请
    METHOD FOR RAPID IDENTIFICATION OF DRUG TARGETS AND DRUG MECHANISMS OF ACTION IN HUMAN CELLS 审中-公开
    快速鉴定药物靶点和药物作用机制的方法

    公开(公告)号：WO2012122017A2

    公开(公告)日：2012-09-13

    申请号：PCT/US2012/027477

    申请日：2012-03-02

    Applicant: CORNELL UNIVERSITY ,  THE ROCKEFELLER UNIVERSITY ,  ELEMENTO, Olivier ,  KAPOOR, Tarun M. ,  WACKER, Sarah A.

    Inventor： ELEMENTO, Olivier ,  WACKER, Sarah A.

    IPC: C12Q1/68

    CPC classification number: G06F19/16 ,  C12Q1/6874 ,  G01N33/5008 ,  G01N2800/44

    Abstract: A method of identification of drug targets and drug resistance mechanisms in human cells of a drug comprising the steps of: generating at least one drug-resistant sample and at least one drug-sensitive sample; analyzing substantial portions of the genome and/or transcriptome of the least one drug-resistant sample and drug-sensitive sample to obtain sequencing data; detecting substantially all alterations in the at least drug-resistant sample; deriving a resistance signature; and performing analysis of the drug resistance signature of at least one recurrently altered gene using bioinformatic tools and cellular biology methods to determine if alteration of the at least one gene of the drug resistance signature is sufficient to confer at least partial resistance to cells or tissues against the drug.

    Abstract translation: 一种鉴定药物人类细胞中的药物靶标和药物抗性机制的方法，包括以下步骤：产生至少一种耐药样品和至少一种药物敏感样品; 分析至少一种耐药样品和药物敏感样品的基因组和/或转录组的大部分，以获得测序数据; 检测至少耐药样品中的基本上全部改变; 导出抵制签名; 以及使用生物信息学工具和细胞生物学方法对至少一种经常改变的基因的药物抗性标记进行分析，以确定所述药物抗性标记的至少一个基因的改变是否足以赋予针对细胞或组织的至少部分抗性 该药。

    METHOD OF DETERMINING WETHER A SUBJECT IS RESISTANT TO CHEMOTHERAPY WITH DNA DAMAGING AGENTS
    70.
    发明申请
    METHOD OF DETERMINING WETHER A SUBJECT IS RESISTANT TO CHEMOTHERAPY WITH DNA DAMAGING AGENTS 审中-公开
    确定一个主题的方法可以抵抗DNA损伤剂的化学疗法

    公开(公告)号：WO2012117107A1

    公开(公告)日：2012-09-07

    申请号：PCT/EP2012/053674

    申请日：2012-03-02

    Applicant: UNIVERSITETET I OSLO ,  EDIN, Nina, F., Jeppesen ,  PETTERSEN, Erik, Olai ,  SANDVIK, Joe, Alexander ,  EBBESEN, Peter

    Inventor： EDIN, Nina, F., Jeppesen ,  PETTERSEN, Erik, Olai ,  SANDVIK, Joe, Alexander ,  EBBESEN, Peter

    IPC: G01N33/50

    CPC classification number: G01N33/5011 ,  G01N33/5091 ,  G01N2333/4703 ,  G01N2800/40 ,  G01N2800/44 ,  G01N2800/52

    Abstract: The present invention relates to a method for determining whether a subject is resistant to certain types of chemotherapy, specifically chemotherapy in which DNA damaging agents are used. A method of determining whether a subject is resistant to chemotherapy with DNA damaging agents, said method comprising determining whether a sample from said subject is capable of reducing the low dose hyper-radiosensitivity (HRS) phenotype in HRS proficient cells, said subject being resistant to said chemotherapy if said sample is capable of reducing the HRS phenotype in HRS proficient cells is provided. Preferred methods involve detection of free extracellular TGβ3 in said sample, determining whether the sample has the ability to increase cell survival in cells in response to radiation that induces the HRS phenotype in HRS proficient cells and determining whether said sample has the ability to decrease the mitotic ratio and/or mitotic ratio (irradiated cells/unirradiated cells) in cells in response to radiation that induces the HRS phenotype in HRS proficient cells.

    Abstract translation: 本发明涉及一种用于确定受试者是否耐受某些类型的化疗，特别是使用DNA损伤剂的化学疗法的方法。 一种确定受试者是否耐受DNA损伤剂的化学疗法的方法，所述方法包括确定来自所述受试者的样品是否能够降低HRS精通细胞中的低剂量超辐射敏感性（HRS）表型，所述受试者耐受 如果所述样品能够降低HRS精液细胞中的HRS表型，则表示化疗。 优选的方法包括检测所述样品中的游离细胞外TGβ3，确定样品是否具有增加细胞响应于在HRS精通细胞中诱导HRS表型的辐射的细胞存活的能力，并确定所述样品是否具有减少有丝分裂的能力 比例和/或有丝分裂比（照射细胞/未照射细胞）在细胞中响应于在HRS精通细胞中诱导HRS表型的辐射。

Patent Agency Ranking